NYSE:MRKPharmaceuticals
Should Breakthrough FDA Status for Novel Lung Cancer Drug Prompt Action From Merck (MRK) Investors?
Earlier this week, Daiichi Sankyo and Merck announced that ifinatamab deruxtecan received Breakthrough Therapy Designation from the U.S. FDA for adults with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy, based on promising early clinical data.
This marks the first Breakthrough Therapy Designation for ifinatamab deruxtecan, accelerating its development and highlighting its potential to address an unmet need in oncology.
Now, we’ll consider how...